Hepatitis C treatment in patients on the liver transplant waiting list

This review suggests that although IFN–free therapies represent a tremendous advance in the ability to cure this previously difficult to treat population, additional data on the safety of these regimens, particularly in patients with severely decompensated cirrhosis, the consequences of virologic failure and the impact of viral eradication on short– and long–term liver function are urgently needed.